Alector, Inc.

Good day, and thank you for standing by. Welcome to Electors Q4 2023 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during a session, you will need to press star 11 on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker for today, Katie Hogan. Please go ahead.

Thank you, Operator, and hello, everyone. Earlier this afternoon, we released our financial results for the fourth quarter and full year 2023. The press release is available on our website at www.elector.com. And our 10-K was filed with the Securities and Exchange Commission this afternoon. Joining me on the call today are Dr. Arnon Rosenthal, co-founder and CEO, Dr. Sarah Kankari Mitra, President and Head of Research and Development, Dr. Gary Romano, Chief Medical Officer, and Dr. Mark Grasso, Chief Financial Officer. After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we'll be making a number of forward-looking statements. Please take a moment to review our slide in the webcast, which contains our forward-looking statement disclosure. And we also encourage you to review our SEC filings for more information. I would now like to turn the call over to Arnon Rosenthal, Chief Executive Officer. Arnon?

Thank you, Katie. Good afternoon, everyone. And thank you for joining Elektor for our first quarter and full year 2023 financial results conference call. I'll begin by highlighting the broad mechanistic potential of our immunoneurology candidates. Our candidates recruit microglia, the brain's primary immune cells, to combat neurodegeneration by containing multiple classes of misfolded protein, maintaining brain health and neuronal function, and supporting the maintenance of healthy synapses, astrocytes, oligodendrocytes, the blood-brain barrier, and the vasculature. By harnessing microglia, our candidates aim to comprehensively address the complex pathology of neurodegenerative diseases, potentially providing long-lasting clinical benefits across multiple disease stages. Our investigational drug candidates have the potential to be effective as standalone therapies or in combination with other treatments, particularly those targeting misfolded proteins. The broad disease fighting mechanisms that our drugs activate, as well as the potential synergy between our immunoneurology candidates and therapies directed against misfolded proteins, has the potential to elicit a more potent therapeutic benefit with longer durability and better efficacy at multiple disease stages compared to current therapies against misfolded proteins. As we reflect on the past year, I am pleased to highlight that 2023 was marked by successful clinical execution and clarity around timelines for our advanced clinical development program. We achieved significant milestones in our late-stage programs, reinforcing electros standing as a pioneer in immunoneurology. Importantly, we completed trial enrollment for our two lead programs. This includes the pivotal and front three, phase three trial of our progranulin-elevating candidate, latuzinamab, in front of temporal dementia with progranulin gene mutation, or FTD-GRN, and invoke two phase two trial of our TRAM2 candidate AL002 in early Alzheimer's disease. In partnership with GSK, we also recently dozed the first participant in PROGRESS-AD, the phase two clinical trial of AL101 in early Alzheimer's disease. Furthermore, in February 2024, the FDA granted breakthrough therapy designation to latosinamab for FTD-GRN. marking another significant achievement. It is worth noting that although FTD is a complex disease clinically, we have developed a straightforward approach to correcting progranuling deficiency, the underlying cause of the disease. Collectively, these advancements move us closer to potential meaningful data readout this year and next. In January, we also further strengthened our balance sheet with the completion of $75 million follow-on financing, which Mark will touch on further. Later in this call, Sarah will provide insight in our early research and development efforts, including Alecto's brain carrier technology platform. Our commitment to addressing older generation remains unwavering, and with our advanced pipeline, strong cash position, we are well-equipped for meaningful value creation in the next phase of our growth. This year, we'll continue to focus on delivering and translating our progress into meaningful impact. An important event will be the anticipated data readout from Invoke 2, Phase 2 trial of L002 in the first quarter. This will potentially be a major step forward in elucidating our immunoneurology hypothesis. Together with the support from our partners, we are committed to advancing all the generative disease research, reflecting our firm belief in immunoneurology, in the immunoneurology potential. With that, I will turn it over to Gary to talk about our goals and expectations for our clinical development program. Gary?